AME case reports · 2026
A successful treatment of urticaria pigmentosa with omalizumab in a pediatric patient: a case report.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alhajri Abdulmohsen, Hussain Albaqshi Mohammed Abdullah, Almarzooq Zainab Yousef, Aljughayman Mohammed Abdullah, Almulla Sarah Anwar, Alkhalifa Fajr Saad, Alsindi Zahra Saleh
Аннотация
BACKGROUND: Cutaneous mastocytosis (CM) is a rare disorder characterized by abnormal mast cell proliferation limited to the skin. Conventional treatments including antihistamines and corticosteroids often provide suboptimal symptom control, with less than 50% of patients responding adequately to H1-antihistamine therapy. Omalizumab, a humanized monoclonal antibody that inhibits immunoglobulin E (IgE) binding to mast cells, represents a promising therapeutic alternative for refractory cases.
CASE DESCRIPTION: We report a 14-year-old Middle Eastern female with a 1-year history of intensely pruritic, hyperpigmented macules significantly impacting her quality of life. Physical examination revealed widespread excoriated erythematous and brown macules with positive Darier's sign. Histopathological examination showed CD117-positive mast cells, confirming CM diagnosis. Laboratory investigations were normal except for mildly elevated IgE (217 IU/mL). Conventional management with antihistamines, corticosteroids, and Montelukast provided minimal improvement, with persistent urticarial attacks requiring systemic steroid pulses. Omalizumab was initiated at 150 mg monthly subcutaneously and increased to 300 mg monthly due to relapses. Following dose optimization, the patient achieved complete symptom resolution and improved quality of life without adverse events.
CONCLUSIONS: This represents the first documented pediatric CM case in Saudi Arabia successfully treated with omalizumab. The treatment demonstrated remarkable efficacy when conventional therapies failed, with excellent safety profile. Omalizumab may serve as a viable therapeutic alternative for pediatric patients with refractory CM. Further clinical trials are needed to establish optimal treatment protocols.
CASE DESCRIPTION: We report a 14-year-old Middle Eastern female with a 1-year history of intensely pruritic, hyperpigmented macules significantly impacting her quality of life. Physical examination revealed widespread excoriated erythematous and brown macules with positive Darier's sign. Histopathological examination showed CD117-positive mast cells, confirming CM diagnosis. Laboratory investigations were normal except for mildly elevated IgE (217 IU/mL). Conventional management with antihistamines, corticosteroids, and Montelukast provided minimal improvement, with persistent urticarial attacks requiring systemic steroid pulses. Omalizumab was initiated at 150 mg monthly subcutaneously and increased to 300 mg monthly due to relapses. Following dose optimization, the patient achieved complete symptom resolution and improved quality of life without adverse events.
CONCLUSIONS: This represents the first documented pediatric CM case in Saudi Arabia successfully treated with omalizumab. The treatment demonstrated remarkable efficacy when conventional therapies failed, with excellent safety profile. Omalizumab may serve as a viable therapeutic alternative for pediatric patients with refractory CM. Further clinical trials are needed to establish optimal treatment protocols.